[
    {
        "pregunta": "1. These questions cover diagnosis, classification, clinical features, management, and follow-up of Juvenile Idiopathic Arthritis based on current guideline principles.",
        "respuesta": "The provided information does not include detailed guideline principles specifically for the **diagnosis, classification, clinical features, management, and follow-up of Juvenile Idiopathic Arthritis (JIA)**.\n\nWhat is available is a broad statement that the 2021 American College of Rheumatology (ACR) guidelines for JIA focus on persons already diagnosed with JIA and emphasize:\n\n- Early diagnosis and evaluation to optimize outcomes.\n- Use of disease-modifying antirheumatic drugs (DMARDs) and a treat-to-target management strategy consistent with ACR pharmacologic treatment guidelines.\n- Recognition that patients have varied disease manifestations and experiences.\n- A shared decision-making process to tailor treatment plans.\n- The guidelines do **not** address coexisting extraarticular conditions (uveitis, psoriasis, inflammatory bowel disease) that influence management.\n\nFor detailed principles on diagnosis, classification, and follow-up, the current document does not provide sufficient information.\n\nIf you need, I can help find or summarize separate comprehensive guidelines specific to JIA diagnosis and management upon request.",
        "contexto": [
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "of pharmacologic intervention addressed in the recommendations are shown in Table 1 Rosters of the Core Leadership Team, Literature Review Team, and both panels are included in Supplementary Appendix 5 ( https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract Guiding principles The development of the recommendations presented herein was guided by the following principles: 1. Consistent with the ACR's 2019 JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "<h1>Table 2. Guiding principles for the integrative management of rheumatoid arthritis*</h1>",
            "<p>| <strong>Guiding principles for the integrative management of rheumatoid arthritis</strong> |\n|-------------------------------------------------------------------------------|\n| Rheumatoid arthritis is a chronic, systemic inflammatory condition that requires early diagnosis, evaluation, and management to achieve optimal outcomes. |\n| Rheumatoid arthritis should be treated with disease-modifying antirheumatic drugs and follow a treat-to-target management strategy, as detailed in the 2021 ACR Rheumatoid Arthritis Pharmacologic Treatment Guidelines (1). |\n| Individuals with chronic diseases like rheumatoid arthritis seek many available therapies to maintain physical function, reduce pain, and improve their quality of life. |\n| Treatment decisions should follow a shared decision-making process. Individuals with rheumatoid arthritis present with a variety of manifestations and experiences. |"
        ]
    },
    {
        "pregunta": "2. ¿Cuál es el csDMARD preferido para la AIJ oligoarticular y por qué?",
        "respuesta": "La información proporcionada no especifica un csDMARD (fármaco antirreumático modificador de la enfermedad sintético convencional) preferido para la Artritis Idiopática Juvenil (AIJ) oligoarticular. Sin embargo, se menciona que para oligoartritis activa con respuesta inadecuada o intolerancia a AINEs e infiltraciones intraarticulares (IAGCs) y al menos un csDMARD, se recomiendan fuertemente los bDMARDs, sin preferencia por uno específico.\n\nPor lo tanto, no hay datos suficientes en la información disponible para indicar cuál es el csDMARD preferido en AIJ oligoarticular ni la razón de dicha preferencia.",
        "contexto": [
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity measures is conditionally recommended",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "preferred bDMARD. Voting panelists deferred recommending a specific bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice Some voting panelists preferred starting with a short-acting agent such as anakinra, but in the absence of controlled studies, no preferred agent was endorsed. Patients/caregivers noted preference for fewer injections, if possible. As response to individual agents is variable, switching among and between IL-1 and IL-6 inhibitors when needed due to lack of efficacy or poor tolerability is appropriate. Concerns were expressed",
            "of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and Patient/Caregiver Panel both engaged in vigorous discussions over the use of NSAIDs and oral glucocorticoids Another major change in recommendations for the treatment of systemic JIA is the use of bDMARDs as initial treatment or upon inadequate response to a short course of NSAIDs. The addition of csDMARDs is recommended only for persistent synovitis despite treatment with bDMARDs. This recommendation reflects growing understanding about the roles of specific cytokines in systemic JIA and the ability to induce remission with targeted therapy against IL-6 and IL-1 The use of IAGCs was extensively discussed. Recommendations from 2011 and 2019 to preferentially use triamcinolone hexacetonide for oligoarthritis There is much that remains to be learned. Studies must be performed to obtain high-quality data to fill in the evidentiary gaps"
        ]
    },
    {
        "pregunta": "3. What is the role of calcineurin inhibitors in systemic JIA with MAS, and how do they compare to IL-1 or IL-6 inhibitors?",
        "respuesta": "Según la información proporcionada, en la artritis idiopática juvenil sistémica (AIJs) con síndrome de activación macrófágica (SAM):\n\n- Los inhibidores de la calcineurina se utilizan en el manejo del SAM, pero los inhibidores de interleucina-1 (IL-1) y de interleucina-6 (IL-6) están **recomendados de forma condicional sobre el uso exclusivo de inhibidores de la calcineurina** para lograr la inactivación de la enfermedad y la resolución del SAM.\n\n- No hay un agente preferido específico dentro de los inhibidores de IL-1 o IL-6.\n\n- La evidencia que respalda esta recomendación es de **muy baja certeza**.\n\n- En casos de resistencia o respuesta parcial a la terapia biológica (incluyendo inhibidores de IL-1 o IL-6), no se ha establecido claramente que la adición de inhibidores de la calcineurina sea superior a otras opciones como etopósido, inmunoglobulina intravenosa o plasmaféresis.\n\nEn resumen, los inhibidores de IL-1 o IL-6 son preferidos condicionalmente sobre los inhibidores de la calcineurina solos en el tratamiento de la AIJs con SAM, aunque los datos son de muy baja calidad y no se establece un agente preferido.",
        "contexto": [
            "<p>|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|\n|---|---|---|---|\n|Formal recommendation deferred|Very low|PICO 24. In patients with systemic JIA, does the presence of subclinical MAS alter the treatment paradigm?|130|\n|IL-1 and IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS.|Very low|PICO 25. In patients with systemic JIA and overt MAS, is biologic therapy superior to calcineurin inhibitors for achievement of inactive disease and resolution of MAS?|131–136|\n|Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. There is no preferred agent.| | | |\n|Formal recommendation deferred|Very low|PICO 26. For nonresponse or partial response to biologic therapy, is addition of a calcineurin inhibitor superior to etoposide or IVIG or plasmapheresis for achievement of inactive disease and resolution of MAS?|137–138|",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>",
            "<ul>\n<li>Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD). TNFi = tumor necrosis factor inhibitor; MTX = methotrexate; IL-17i = interleukin-17 inhibitor; IV = intravenous.</li>\n</ul>\n\n<p>† When there were no published studies, we relied on the clinical experience of the panelists, which was designated very-low-quality evidence.</p>",
            "for inadequate response to or intolerance of NSAIDs and/or glucocorticoids for systemic JIA without MAS. Most physicians and patients/caregivers preferred quickly starting IL-1 or IL-6 inhibitors for insufficient response to NSAIDs or glucocorticoids Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent. Given the potential toxicities from long-term use of glucocorticoids Systemic JIA with MAS: initial therapy (Table 6 Infections can trigger MAS; therefore, all persons with MAS should be evaluated for infection concurrently with or prior to initiation of therapy Biologic DMARDs IL-1 or IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS for systemic JIA with MAS. There is no preferred agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 6. Systemic JIA with MAS*</h1>"
        ]
    },
    {
        "pregunta": "4. What are the potential long-term complications of untreated or poorly controlled JIA?",
        "respuesta": "La información proporcionada no incluye datos específicos sobre las posibles complicaciones a largo plazo de la artritis idiopática juvenil (AIJ) no tratada o mal controlada. No se dispone de detalles en las guías citadas para describir estas complicaciones de manera confiable.\n\nSi desea, puedo ayudar a buscar o resumir información de otras fuentes reconocidas sobre este tema.",
        "contexto": [
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "(oral)</strong><br><strong>Varicella</strong><br><strong>Zoster</strong><br><strong>Yellow fever</strong> | <strong>Rheumatoid arthritis</strong><br><strong>Psoriatic arthritis</strong><br><strong>Ankylosing spondylitis</strong><br><strong>Spondyloarthritis</strong><br><strong>Enthesitis-related arthritis</strong><br><strong>IBD-associated arthritis</strong><br><strong>Juvenile idiopathic arthritis</strong> |",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "and very low quality. The exceptions listed for the first recommendation above, including delay for personal reasons or other ongoing medical comorbidities, apply to this recommendation as well. Patients who have an acute flare of their OA or other inflammatory arthropathy (e.g., gout, calcium pyrophosphate deposition disease) may be interested in delaying TJA for treatment with a glucocorticoid injection to provide immediate pain relief. There are, however, potential harms associated with delaying surgery for glucocorticoid injection treatment, particularly in patients with diabetes mellitus who have an increased risk of hyperglycemia with intraarticular glucocorticoids or the increased risk of joint infection if the surgery is performed within 3 months of the intraarticular injection In our defined population, we conditionally recommend proceeding to TJA without delay over delaying surgical treatment for a trial of viscosupplementation injections. This recommendation is conditional"
        ]
    },
    {
        "pregunta": "5. ¿Cuál es la recomendación inicial para el tratamiento de la AIJ sistémica sin síndrome de activación macrofágica (MAS)?",
        "respuesta": "La recomendación inicial para el tratamiento de la artritis idiopática juvenil (AIJ) sistémica sin síndrome de activación macrófaga (SAM) es el uso condicional de fármacos biológicos modificadores de la enfermedad (bDMARDs), específicamente inhibidores de interleucina-1 (IL-1) o interleucina-6 (IL-6), como monoterapia inicial. No se prefiere un agente específico dentro de estos inhibidores, aunque algunos panelistas prefieren empezar con un agente de acción corta como anakinra.  \n\nAdemás, se reconoce que la respuesta individual varía y es apropiado cambiar entre inhibidores de IL-1 e IL-6 si es necesario debido a falta de eficacia o mala tolerancia.  \n\nEn resumen, los inhibidores de IL-1 o IL-6 son la primera línea recomendada condicionalmente para AIJ sistémica sin SAM, con énfasis en terapia dirigida y personalizada.",
        "contexto": [
            "preferred bDMARD. Voting panelists deferred recommending a specific bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice Some voting panelists preferred starting with a short-acting agent such as anakinra, but in the absence of controlled studies, no preferred agent was endorsed. Patients/caregivers noted preference for fewer injections, if possible. As response to individual agents is variable, switching among and between IL-1 and IL-6 inhibitors when needed due to lack of efficacy or poor tolerability is appropriate. Concerns were expressed",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>",
            "<h1>Table 1. Recommendations for the initial treatment of patients with active psoriatic arthritis who are OSM- and other treatment–naive (PICOs 9–15)*</h1>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 6. Systemic JIA with MAS*</h1>",
            "of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and Patient/Caregiver Panel both engaged in vigorous discussions over the use of NSAIDs and oral glucocorticoids Another major change in recommendations for the treatment of systemic JIA is the use of bDMARDs as initial treatment or upon inadequate response to a short course of NSAIDs. The addition of csDMARDs is recommended only for persistent synovitis despite treatment with bDMARDs. This recommendation reflects growing understanding about the roles of specific cytokines in systemic JIA and the ability to induce remission with targeted therapy against IL-6 and IL-1 The use of IAGCs was extensively discussed. Recommendations from 2011 and 2019 to preferentially use triamcinolone hexacetonide for oligoarthritis There is much that remains to be learned. Studies must be performed to obtain high-quality data to fill in the evidentiary gaps"
        ]
    },
    {
        "pregunta": "6. How is systemic JIA characterized, and what are its key clinical features?",
        "respuesta": "La información proporcionada no incluye una descripción específica o detallada sobre cómo se caracteriza la artritis idiopática juvenil sistémica (AIJs) ni sus principales características clínicas. Por lo tanto, no hay datos suficientes en las guías y documentos mencionados para ofrecer una respuesta confiable sobre este aspecto.\n\nSi desea, puedo ayudar a buscar o resumir información de otras fuentes reconocidas que aborden la caracterización clínica de la AIJs.",
        "contexto": [
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "(oral)</strong><br><strong>Varicella</strong><br><strong>Zoster</strong><br><strong>Yellow fever</strong> | <strong>Rheumatoid arthritis</strong><br><strong>Psoriatic arthritis</strong><br><strong>Ankylosing spondylitis</strong><br><strong>Spondyloarthritis</strong><br><strong>Enthesitis-related arthritis</strong><br><strong>IBD-associated arthritis</strong><br><strong>Juvenile idiopathic arthritis</strong> |",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 6. Systemic JIA with MAS*</h1>",
            "(oral)</strong><br><strong>Varicella</strong><br><strong>Zoster</strong><br><strong>Yellow fever</strong> | <strong>Systemic lupus erythematosus</strong><br><strong>Sjögren's syndrome</strong><br><strong>Systemic sclerosis</strong><br><strong>Idiopathic inflammatory myopathies</strong><br><strong>Mixed connective tissue disease</strong><br><strong>Undifferentiated connective tissue disease</strong><br><strong>Antiphospholipid antibody syndrome</strong> |"
        ]
    },
    {
        "pregunta": "7. What laboratory tests are recommended for diagnosing JIA?",
        "respuesta": "La información proporcionada no incluye detalles específicos sobre los exámenes de laboratorio recomendados para el diagnóstico de la artritis idiopática juvenil (AIJ). No se dispone de datos suficientes en las guías citadas para determinar cuáles pruebas de laboratorio deben solicitarse para el diagnóstico de AIJ.\n\nSi desea, puedo ayudar a buscar o resumir información de otras fuentes reconocidas sobre los exámenes de laboratorio en AIJ.",
        "contexto": [
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; IAGCs = intraarticular glucocorticoids; DMARDs = disease-modifying antirheumatic drugs; MTX = methotrexate; LEF = leflunomide; SSZ = sulfasalazine; HCQ = hydroxychloroquine; TNFi = tumor necrosis factor inhibitor; TMJ = temporomandibular joint.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 4. TMJ arthritis*</h1>"
        ]
    },
    {
        "pregunta": "8. When should tapering and discontinuation of glucocorticoids be considered in systemic JIA?",
        "respuesta": "La disminución progresiva y la suspensión de glucocorticoides en la artritis idiopática juvenil sistémica (AIJs) se deben considerar **fuertemente recomendadas después de que se haya logrado el estado de enfermedad inactiva**. Esto se fundamenta en evidencia de muy baja certeza que indica que el riesgo de flare con AIJs bien controlada es menor que los posibles daños asociados al uso prolongado de glucocorticoides, incluso en dosis bajas.\n\nPor lo tanto, una vez que el paciente alcanza inactividad de la enfermedad, se debe iniciar el proceso de tapering y eventual discontinuación de glucocorticoides para minimizar efectos adversos en salud ósea, crecimiento, y otros riesgos a largo plazo asociados a la terapia prolongada con esteroides. \n\nEsta recomendación enfatiza que el uso de glucocorticoides debe limitarse a la dosis más baja y duración más corta posible, priorizando la seguridad a largo plazo del paciente.",
        "contexto": [
            "<h1>Table 7. Systemic JIA with inactive disease*</h1>\n\n<p>|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|\n|---|---|---|---|\n|Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained.|Very low|PICO 28. In patients with systemic JIA with inactive disease treated with oral steroids, is taper to discontinuation of steroids superior to continuing long-term stable-dose steroids for preventing disease flare and minimizing side effects/medication toxicity?|139|\n|Tapering and discontinuing biologic DMARDs is conditionally recommended after inactive disease has been attained.|Very low|PICO 29. In patients with systemic JIA in clinical remission with biologic monotherapy, is tapering by decreasing dosage superior to tapering dosing interval at preventing disease exacerbation, preventing development of antidrug antibodies, and minimizing medication toxicity?|140–143|</p>",
            "on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. Inactive systemic JIA with or without history of MAS (Table 7 Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained in systemic JIA. The risk of flare from systemic JIA that is well controlled is considerably outweighed by possible harms from long-term glucocorticoid use, even at low doses Tapering and discontinuing bDMARDs is conditionally recommended after inactive disease has been attained in systemic JIA. In children with systemic JIA whose disease is inactive, it may be possible to maintain this inactive disease state with lower doses of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and",
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "this update, tapering recommendations are made for patients who are in low disease activity or remission in the face of a paucity of data about when and how best to taper. The panel recommended that careful tapering might be considered if the patient wishes to cut back on their use of DMARDs. However, patients should be closely evaluated during any taper, and if a flare occurs, the prior regimen should be reinstituted promptly. Last, this update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision",
            "of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and Patient/Caregiver Panel both engaged in vigorous discussions over the use of NSAIDs and oral glucocorticoids Another major change in recommendations for the treatment of systemic JIA is the use of bDMARDs as initial treatment or upon inadequate response to a short course of NSAIDs. The addition of csDMARDs is recommended only for persistent synovitis despite treatment with bDMARDs. This recommendation reflects growing understanding about the roles of specific cytokines in systemic JIA and the ability to induce remission with targeted therapy against IL-6 and IL-1 The use of IAGCs was extensively discussed. Recommendations from 2011 and 2019 to preferentially use triamcinolone hexacetonide for oligoarthritis There is much that remains to be learned. Studies must be performed to obtain high-quality data to fill in the evidentiary gaps"
        ]
    },
    {
        "pregunta": "9. What factors contribute to the conditional nature of recommendations in the treatment of juvenile idiopathic arthritis?",
        "respuesta": "Los factores que contribuyen a que las recomendaciones para el tratamiento de la artritis idiopática juvenil (AIJ) sean **condicionales** según la información proporcionada incluyen:\n\n- **Evidencia de muy baja certeza** que respalda las recomendaciones, lo que limita la fuerza y confianza en los beneficios observados.\n- **Limitada cantidad de estudios o datos sobre intervenciones específicas en AIJ**, lo que genera incertidumbre en los resultados.\n- **Heterogeneidad en las manifestaciones clínicas y evolución de los pacientes**, dificultando la generalización de recomendaciones firmes.\n- **Ausencia de preferencia clara por agentes específicos**, como en el caso de los bDMARDs para oligoartritis o AIJ sistémica, debido a similitud en efectividad y seguridad o falta de evidencia superior.\n- Importancia de factores individuales y pronóstico, que sugieren la necesidad de adaptar las decisiones terapéuticas en forma personalizada y mediante decisión compartida con pacientes y familias.\n\nEn resumen, la combinación de baja certeza de la evidencia, variabilidad clínica y necesidad de individualización de la terapia son las principales causas para que las recomendaciones sean condicionales en AIJ.",
        "contexto": [
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "<h1>Table 2. Strength of recommendations and quality of supporting evidence*</h1>\n\n<p>|Condition|No. of recommendations|Conditional|Strong|Very low|Low|Moderate|High|\n|---|---|---|---|---|---|---|---|\n|Oligoarthritis|9|5|4|7|2|0|0|\n|TMJ arthritis|7|6|1|7|0|0|0|\n|Systemic JIA|9|5|4|9|0|0|0|\n|Total|25|16|9|23|2|0|0|</p>\n\n<ul>\n<li>TMJ = temporomandibular joint; JIA = juvenile idiopathic arthritis.</li>\n</ul>\n\n<h1>Table 3. Oligoarticular JIA*</h1>"
        ]
    },
    {
        "pregunta": "10. What is the typical age of onset for Juvenile Idiopathic Arthritis?",
        "respuesta": "La información proporcionada no incluye datos sobre la edad típica de inicio de la artritis idiopática juvenil (AIJ). Por lo tanto, no es posible ofrecer una respuesta confiable basada en las guías y documentos disponibles.",
        "contexto": [
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; IAGCs = intraarticular glucocorticoids; DMARDs = disease-modifying antirheumatic drugs; MTX = methotrexate; LEF = leflunomide; SSZ = sulfasalazine; HCQ = hydroxychloroquine; TNFi = tumor necrosis factor inhibitor; TMJ = temporomandibular joint.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 4. TMJ arthritis*</h1>",
            "<h1>Table 2. Strength of recommendations and quality of supporting evidence*</h1>\n\n<p>|Condition|No. of recommendations|Conditional|Strong|Very low|Low|Moderate|High|\n|---|---|---|---|---|---|---|---|\n|Oligoarthritis|9|5|4|7|2|0|0|\n|TMJ arthritis|7|6|1|7|0|0|0|\n|Systemic JIA|9|5|4|9|0|0|0|\n|Total|25|16|9|23|2|0|0|</p>\n\n<ul>\n<li>TMJ = temporomandibular joint; JIA = juvenile idiopathic arthritis.</li>\n</ul>\n\n<h1>Table 3. Oligoarticular JIA*</h1>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>"
        ]
    },
    {
        "pregunta": "11. ¿Cuáles son las recomendaciones específicas para el manejo de la artritis activa de la articulación temporomandibular (ATM) en la AIJ?",
        "respuesta": "La información proporcionada no contiene detalles específicos o recomendaciones concretas para el manejo de la artritis activa de la articulación temporomandibular (ATM) en la artritis idiopática juvenil (AIJ). Por lo tanto, no es posible ofrecer una respuesta confiable basada en las guías y documentos disponibles.\n\nSi lo desea, puedo ayudar a buscar o resumir información adicional de fuentes reconocidas sobre este tema.",
        "contexto": [
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "<h1>Table 2. Strength of recommendations and quality of supporting evidence*</h1>\n\n<p>|Condition|No. of recommendations|Conditional|Strong|Very low|Low|Moderate|High|\n|---|---|---|---|---|---|---|---|\n|Oligoarthritis|9|5|4|7|2|0|0|\n|TMJ arthritis|7|6|1|7|0|0|0|\n|Systemic JIA|9|5|4|9|0|0|0|\n|Total|25|16|9|23|2|0|0|</p>\n\n<ul>\n<li>TMJ = temporomandibular joint; JIA = juvenile idiopathic arthritis.</li>\n</ul>\n\n<h1>Table 3. Oligoarticular JIA*</h1>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; IAGCs = intraarticular glucocorticoids; DMARDs = disease-modifying antirheumatic drugs; MTX = methotrexate; LEF = leflunomide; SSZ = sulfasalazine; HCQ = hydroxychloroquine; TNFi = tumor necrosis factor inhibitor; TMJ = temporomandibular joint.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 4. TMJ arthritis*</h1>",
            "<ul>\n<li>TMJ = temporomandibular joint; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; JIA = juvenile idiopathic arthritis; IAGCs = intraarticular glucocorticoids; DMARDs = disease-modifying antirheumatic drugs; MTX = methotrexate; LEF = leflunomide; SSZ = sulfasalazine; HCQ = hydroxychloroquine; TNFi = tumor necrosis factor inhibitor.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 5. Systemic JIA without MAS*</h1>"
        ]
    },
    {
        "pregunta": "12. ¿Cuándo se considera el uso de bDMARDs en la artritis activa de la ATM?",
        "respuesta": "La información proporcionada indica que para la artritis activa de la articulación temporomandibular (ATM) en la artritis idiopática juvenil (AIJ), **no hay un bDMARD específico preferido** recomendado debido a la limitada cantidad de estudios, que son pequeños y observacionales.\n\nSin embargo, se considera condicionalmente el uso de bDMARDs en general para el manejo de AIJ, especialmente si existe artritis activa que no responde adecuadamente a otros tratamientos como AINEs o infiltraciones intraarticulares. El enfoque debe basarse en la evaluación del riesgo de mal pronóstico y la actividad de la enfermedad, considerando las características individuales del paciente.\n\nEn resumen, aunque los bDMARDs pueden ser considerados para la artritis activa de ATM en AIJ, no hay recomendaciones específicas sobre cuándo iniciar su uso en este contexto, ni preferencia por un agente particular, debido a la falta de evidencia suficiente.",
        "contexto": [
            "should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity measures is conditionally recommended",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "preferred bDMARD. Voting panelists deferred recommending a specific bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice Some voting panelists preferred starting with a short-acting agent such as anakinra, but in the absence of controlled studies, no preferred agent was endorsed. Patients/caregivers noted preference for fewer injections, if possible. As response to individual agents is variable, switching among and between IL-1 and IL-6 inhibitors when needed due to lack of efficacy or poor tolerability is appropriate. Concerns were expressed",
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and Patient/Caregiver Panel both engaged in vigorous discussions over the use of NSAIDs and oral glucocorticoids Another major change in recommendations for the treatment of systemic JIA is the use of bDMARDs as initial treatment or upon inadequate response to a short course of NSAIDs. The addition of csDMARDs is recommended only for persistent synovitis despite treatment with bDMARDs. This recommendation reflects growing understanding about the roles of specific cytokines in systemic JIA and the ability to induce remission with targeted therapy against IL-6 and IL-1 The use of IAGCs was extensively discussed. Recommendations from 2011 and 2019 to preferentially use triamcinolone hexacetonide for oligoarthritis There is much that remains to be learned. Studies must be performed to obtain high-quality data to fill in the evidentiary gaps"
        ]
    },
    {
        "pregunta": "13. What is the role of antinuclear antibodies (ANA) in the evaluation of JIA patients?",
        "respuesta": "La información proporcionada no incluye datos específicos sobre el papel de los anticuerpos antinucleares (ANA) en la evaluación de pacientes con artritis idiopática juvenil (AIJ). Por lo tanto, no es posible ofrecer una respuesta confiable basada en las guías y documentos disponibles.",
        "contexto": [
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 6. Systemic JIA with MAS*</h1>",
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>"
        ]
    },
    {
        "pregunta": "14. ¿Por qué se recomienda evitar el uso de glucocorticoides orales como monoterapia inicial en AIJ sistémica sin MAS?",
        "respuesta": "Se recomienda evitar el uso de glucocorticoides orales como monoterapia inicial en la artritis idiopática juvenil sistémica (AIJs) sin síndrome de activación macrófaga (SAM) porque, aunque pueden aliviar síntomas rápidamente, su uso prolongado presenta riesgos importantes para la salud ósea y el crecimiento en niños. Además, los glucocorticoides orales no controlan adecuadamente las manifestaciones sistémicas típicas de la enfermedad.\n\nPor ello, la recomendación es condicional, priorizando el uso de inhibidores de IL-1 o IL-6 como primera línea, reservando los glucocorticoides para el control rápido inicial y limitando su uso a la dosis más baja y duración más corta posible.",
        "contexto": [
            "disease and resolution of MAS for systemic JIA with MAS. There is no preferred agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the treatment of systemic JIA and MAS Glucocorticoids Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. The benefits of glucocorticoids for MAS often outweigh their risks, even in patients whose MAS is triggered by infection. Systemic glucocorticoids may be necessary for severely ill patients because they can have a rapid onset of action. However, although treatment with high-dose glucocorticoids may be required for disease control, subsequent glucocorticoid therapy should be limited to the lowest effective dosage for the shortest duration possible. Longer-term glucocorticoid therapy in children is not appropriate because of its effects on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term",
            "to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy at controlling systemic features that are typically present at onset of disease, leading to a continued need for glucocorticoids Systemic JIA without MAS: subsequent therapy (Table 5 IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of csDMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids for systemic JIA without MAS. Most physicians and patients/caregivers",
            ". However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and limited efficacy (unless inactive disease is achieved). Voting panelists could not agree on the appropriate duration of initial use before escalating therapy, as some panelists prefer that the use of NSAIDs be avoided altogether. Glucocorticoids IAGCs are conditionally recommended as part of initial therapy for active TMJ arthritis. There is no preferred agent. IAGCs may alleviate joint symptoms and help restore function. This recommendation is conditional, as there have been unique TMJ-specific serious adverse events, including heterotopic ossification and impaired growth Oral glucocorticoids are conditionally recommended against as part of initial therapy for active TMJ arthritis. If, despite recommendations against, oral glucocorticoids are given to quickly alleviate severe symptoms prior to the onset of action of DMARDs, treatment should be limited to the lowest",
            "on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. Inactive systemic JIA with or without history of MAS (Table 7 Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained in systemic JIA. The risk of flare from systemic JIA that is well controlled is considerably outweighed by possible harms from long-term glucocorticoid use, even at low doses Tapering and discontinuing bDMARDs is conditionally recommended after inactive disease has been attained in systemic JIA. In children with systemic JIA whose disease is inactive, it may be possible to maintain this inactive disease state with lower doses of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and",
            "for inadequate response to or intolerance of NSAIDs and/or glucocorticoids for systemic JIA without MAS. Most physicians and patients/caregivers preferred quickly starting IL-1 or IL-6 inhibitors for insufficient response to NSAIDs or glucocorticoids Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent. Given the potential toxicities from long-term use of glucocorticoids Systemic JIA with MAS: initial therapy (Table 6 Infections can trigger MAS; therefore, all persons with MAS should be evaluated for infection concurrently with or prior to initiation of therapy Biologic DMARDs IL-1 or IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS for systemic JIA with MAS. There is no preferred agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the"
        ]
    },
    {
        "pregunta": "15. What non-pharmacologic interventions are recommended for children with JIA?",
        "respuesta": "La información proporcionada no incluye recomendaciones específicas sobre intervenciones no farmacológicas para niños con artritis idiopática juvenil (AIJ). Por lo tanto, no es posible ofrecer una respuesta confiable basada en las guías y documentos disponibles.  \n\nSi desea, puedo ayudar a buscar o resumir información adicional de fuentes reconocidas sobre intervenciones no farmacológicas en AIJ.",
        "contexto": [
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "<p>|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|\n|---|---|---|---|\n|A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy.|Very low|PICO 11. In children with JIA with active TMJ arthritis, should a trial of scheduled NSAIDs be recommended, and should there be any preferred NSAID treatment?|53|\n|IAGCs are conditionally recommended as part of initial therapy.|Very low|PICO 12. In children with JIA with active TMJ arthritis, should adding intraarticular glucocorticoids to initial therapy be recommended?|53–57|\n|There is no preferred agent.|Very low|PICO 14. In children with JIA with active TMJ arthritis, should a specific steroid type be recommended for intraarticular injection?|58|\n|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|"
        ]
    },
    {
        "pregunta": "16. When should disease-modifying antirheumatic drugs (DMARDs) be initiated in JIA management?",
        "respuesta": "La información proporcionada no especifica de manera directa **cuándo se deben iniciar los fármacos modificadores de la enfermedad (FAME)** en el manejo de la artritis idiopática juvenil (AIJ).  \n\nSin embargo, se menciona:  \n- En oligoartritis activa, tras respuesta inadecuada o intolerancia a AINEs e infiltraciones intraarticulares, se recomienda condicionalmente el uso de bDMARDs, usualmente precedidos o asociados a csDMARD.  \n- Se recomienda considerar los factores de riesgo para mal pronóstico (como afectación de ciertas articulaciones, presencia de enfermedad erosiva, niveles elevados de inflamación, enfermedad simétrica) para guiar decisiones terapéuticas, lo cual puede influir en la decisión de iniciar FAME.  \n- También se enfatiza el uso de medidas validadas de actividad de enfermedad para guiar el tratamiento bajo un enfoque de treat-to-target.  \n- En AIJ sistémica sin síndrome de activación macrófaga, se prefieren condicionalmente inhibidores de IL-1 o IL-6 como tratamiento inicial, evitando glucocorticoides orales como monoterapia.  \n\nPor lo tanto, aunque no hay un punto exacto de inicio que se detalle claramente, el inicio de FAME se realiza condicionado por:  \n- Actividad persistente o insuficiente respuesta a tratamientos iniciales (AINEs, infiltraciones).  \n- Presencia de factores de mal pronóstico.  \n- La evaluación integral e individualizada del paciente bajo un enfoque que busca inactividad o control óptimo de la enfermedad.  \n\n**No se dispone de una recomendación definitiva o estricta sobre el momento exacto para iniciar FAME solo con la información proporcionada.**",
        "contexto": [
            "<ul>\n<li>RA = rheumatoid arthritis; AS = ankylosing spondylitis; PsA = psoriatic arthritis; JIA = juvenile idiopathic arthritis; DMARDs = disease-modifying antirheumatic drugs; TJA = total joint arthroplasty.</li>\n</ul>\n\n<p>† Apremilast is a change from the prior recommendation.</p>\n\n<p>‡ Indicates a change from the prior recommendation.</p>",
            "thought it was unlikely that patients' priorities regarding the risk of flare versus the risk of infection would have changed. The updated medication list includes medications introduced to treat RA and SpA, including AS and PsA. We have included perioperative management recommendations for the recently introduced JAK-targeted therapies, baricitinib and upadacitinib, in addition to tofacitinib. We have included new management recommendations for the interleukin-17 (IL-17) blocking agent ixekizumab, the IL-23blocking drug, guselkumab, and the novel synthetic DMARD apremilast. Anifrolumab, approved by the FDA on July 30, 2021, and voclosporin, approved January 22, 2021, were included in this guideline, although there is no information regarding their use in the perioperative period. They increase the risk of infection, and therefore the use of these medications in patients with severe SLE would merit review by the treating rheumatologist in consideration of surgery. The Voting Panel",
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>"
        ]
    },
    {
        "pregunta": "17. ¿Cuáles son los riesgos asociados con el uso de glucocorticoides orales en el manejo inicial de la AIJ?",
        "respuesta": "Los riesgos asociados con el uso de glucocorticoides orales en el manejo inicial de la artritis idiopática juvenil (AIJ) incluyen efectos negativos importantes sobre la **salud ósea** y el **crecimiento** en los niños. Por esta razón, su uso prolongado no es apropiado y se recomienda limitar la dosis al mínimo efectivo y la duración al tiempo más corto posible.\n\nAdemás, en el contexto de la AIJ sistémica sin síndrome de activación macrófaga, los glucocorticoides orales no controlan adecuadamente las manifestaciones sistémicas y por ello se recomienda evitarlos como monoterapia inicial.\n\nEn resumen, se recomienda evitar los glucocorticoides orales como monoterapia inicial en AIJ debido a los riesgos para la salud ósea, el crecimiento y la limitada eficacia para controlar la enfermedad sistémica, priorizando tratamientos biológicos específicos y el uso restringido y cuidadoso de glucocorticoides en dosis bajas y por tiempo limitado.",
        "contexto": [
            "3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints",
            ". However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and limited efficacy (unless inactive disease is achieved). Voting panelists could not agree on the appropriate duration of initial use before escalating therapy, as some panelists prefer that the use of NSAIDs be avoided altogether. Glucocorticoids IAGCs are conditionally recommended as part of initial therapy for active TMJ arthritis. There is no preferred agent. IAGCs may alleviate joint symptoms and help restore function. This recommendation is conditional, as there have been unique TMJ-specific serious adverse events, including heterotopic ossification and impaired growth Oral glucocorticoids are conditionally recommended against as part of initial therapy for active TMJ arthritis. If, despite recommendations against, oral glucocorticoids are given to quickly alleviate severe symptoms prior to the onset of action of DMARDs, treatment should be limited to the lowest",
            "and very low quality. The exceptions listed for the first recommendation above, including delay for personal reasons or other ongoing medical comorbidities, apply to this recommendation as well. Patients who have an acute flare of their OA or other inflammatory arthropathy (e.g., gout, calcium pyrophosphate deposition disease) may be interested in delaying TJA for treatment with a glucocorticoid injection to provide immediate pain relief. There are, however, potential harms associated with delaying surgery for glucocorticoid injection treatment, particularly in patients with diabetes mellitus who have an increased risk of hyperglycemia with intraarticular glucocorticoids or the increased risk of joint infection if the surgery is performed within 3 months of the intraarticular injection In our defined population, we conditionally recommend proceeding to TJA without delay over delaying surgical treatment for a trial of viscosupplementation injections. This recommendation is conditional",
            "disease and resolution of MAS for systemic JIA with MAS. There is no preferred agent. IL-1 and IL-6 inhibitors have proven to be very helpful in the treatment of systemic JIA and MAS Glucocorticoids Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. The benefits of glucocorticoids for MAS often outweigh their risks, even in patients whose MAS is triggered by infection. Systemic glucocorticoids may be necessary for severely ill patients because they can have a rapid onset of action. However, although treatment with high-dose glucocorticoids may be required for disease control, subsequent glucocorticoid therapy should be limited to the lowest effective dosage for the shortest duration possible. Longer-term glucocorticoid therapy in children is not appropriate because of its effects on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term",
            "<p>|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|\n|---|---|---|---|\n|A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy.|Very low|PICO 11. In children with JIA with active TMJ arthritis, should a trial of scheduled NSAIDs be recommended, and should there be any preferred NSAID treatment?|53|\n|IAGCs are conditionally recommended as part of initial therapy.|Very low|PICO 12. In children with JIA with active TMJ arthritis, should adding intraarticular glucocorticoids to initial therapy be recommended?|53–57|\n|There is no preferred agent.|Very low|PICO 14. In children with JIA with active TMJ arthritis, should a specific steroid type be recommended for intraarticular injection?|58|\n|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|"
        ]
    },
    {
        "pregunta": "18. How is disease activity monitored in patients with JIA?",
        "respuesta": "La información proporcionada indica que en la artritis idiopática juvenil (AIJ) se **recomienda de manera condicional el uso de medidas validadas de actividad de la enfermedad para guiar las decisiones de tratamiento**, especialmente para facilitar enfoques de treat-to-target (tratamiento dirigido a objetivos).  \n\nNo se especifican en detalle cuáles son estas medidas validadas, pero se resalta la importancia de su utilización formal para evaluar la actividad, monitorear la evolución y ajustar la terapia en función del grado de control de la enfermedad.\n\nEn resumen, el monitoreo de la actividad de la enfermedad en AIJ debe realizarse mediante la evaluación formal y periódica con instrumentos validados que permitan una toma de decisiones clínica guiada, aunque no se detallan en la información las herramientas específicas a emplear.",
        "contexto": [
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches. Treatment for oligoarthritis can and should be modified based on the involvement of specific joints or disease features Voting panelists conditionally recommended formal assessment of disease activity using validated measures. There are several validated disease activity measures for childhood arthritis Treat-to-target approaches have been strongly endorsed for polyarticular JIA Active TMJ arthritis (Figure 2 4 NSAIDs A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active TMJ arthritis. NSAIDs have long been the cornerstone of treatment for JIA and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and limited efficacy (unless inactive",
            "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis  National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH  American College of Rheumatology      BB3F36A39CF1E994D9496BB4A2F6F5BE 10.1002/art.42037 Submitted for publication July 7, 2021; accepted in revised form November 23, 2021.  INTRODUCTION Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines Following the selection of topics, we developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE)",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>"
        ]
    },
    {
        "pregunta": "19. ¿Qué inhibidores biológicos son recomendados para el tratamiento inicial de la AIJ sistémica sin MAS?",
        "respuesta": "Para el tratamiento inicial de la artritis idiopática juvenil (AIJ) sistémica **sin síndrome de activación macrófaga (SAM)**, se recomiendan **de forma condicional** los fármacos biológicos modificadores de la enfermedad (bDMARDs) inhibidores de **interleucina-1 (IL-1)** y **interleucina-6 (IL-6)** como monoterapia inicial.\n\n- No hay un agente biológico preferido dentro de los inhibidores de IL-1 o IL-6.  \n- Algunos panelistas prefieren comenzar con un agente de acción corta, como anakinra, aunque esto no está formalmente establecido debido a la falta de estudios controlados específicos.  \n- Se considera apropiado cambiar entre inhibidores de IL-1 e IL-6 según la respuesta o tolerancia individual.  \n- Estos tratamientos son muy efectivos y bien tolerados, y su uso como primera línea se ha adoptado rápidamente en la práctica clínica.\n\nEn resumen, para AIJ sistémica sin SAM, se recomienda condicionalmente iniciar tratamiento con inhibidores biológicos de IL-1 o IL-6, sin preferencia específica por un agente en particular.",
        "contexto": [
            "|Biologic DMARDs (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy.|Very low|PICO 22. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should biologic treatment (anakinra, canakinumab, tocilizumab, or others) be used as initial therapy, and is there a preferred order?|69–71|\n|There is no preferred agent.| | | |\n|IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of conventional synthetic DMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids.|Very low|PICO 23. In patients with systemic JIA without MAS who do not respond to initial therapy with nonbiologic treatments (NSAIDs, glucocorticoids, DMARDs), should nonbiologic treatments be combined or biologic treatment started?|72–130|",
            "preferred bDMARD. Voting panelists deferred recommending a specific bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice Some voting panelists preferred starting with a short-acting agent such as anakinra, but in the absence of controlled studies, no preferred agent was endorsed. Patients/caregivers noted preference for fewer injections, if possible. As response to individual agents is variable, switching among and between IL-1 and IL-6 inhibitors when needed due to lack of efficacy or poor tolerability is appropriate. Concerns were expressed",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>",
            "<p>|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|\n|---|---|---|---|\n|Formal recommendation deferred|Very low|PICO 24. In patients with systemic JIA, does the presence of subclinical MAS alter the treatment paradigm?|130|\n|IL-1 and IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS.|Very low|PICO 25. In patients with systemic JIA and overt MAS, is biologic therapy superior to calcineurin inhibitors for achievement of inactive disease and resolution of MAS?|131–136|\n|Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. There is no preferred agent.| | | |\n|Formal recommendation deferred|Very low|PICO 26. For nonresponse or partial response to biologic therapy, is addition of a calcineurin inhibitor superior to etoposide or IVIG or plasmapheresis for achievement of inactive disease and resolution of MAS?|137–138|",
            "<ul>\n<li>JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.</li>\n</ul>\n\n<p>† In Supplementary Appendix 3, on the Arthritis &amp; Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.</p>\n\n<h1>Table 7. Systemic JIA with inactive disease*</h1>"
        ]
    },
    {
        "pregunta": "20. ¿Por qué se prefieren los bDMARDs sobre la combinación o cambio entre csDMARDs en la AIJ oligoarticular?",
        "respuesta": "Los fármacos biológicos modificadores de la enfermedad (bDMARDs) se prefieren sobre la combinación o el cambio entre fármacos sintéticos modificadores de la enfermedad (csDMARDs) en la artritis idiopática juvenil (AIJ) oligoarticular debido a que los bDMARDs tienen una **mayor probabilidad de lograr una mejoría rápida y sostenida** en la actividad de la enfermedad. Esta preferencia se basa en evidencia que indica que, en pacientes con respuesta inadecuada o intolerancia a AINEs e infiltraciones intraarticulares, el uso de bDMARDs es más eficaz para controlar la artritis activa que cambiar o combinar otros csDMARDs.\n\nAunque no hay un bDMARD preferido específico, se reconoce como fuerte recomendación su uso en este contexto. Además, se afirma que los bDMARDs son más efectivos y mejor tolerados, favoreciendo un mejor resultado clínico en comparación con las estrategias únicamente con csDMARDs.\n\nEn resumen, la preferencia por bDMARDs sobre la combinación o cambio de csDMARDs en AIJ oligoarticular se fundamenta en su mayor eficacia para lograr respuesta rápida y sostenida en pacientes con enfermedad activa no controlada por tratamientos iniciales.",
        "contexto": [
            "should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity measures is conditionally recommended",
            "of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and Patient/Caregiver Panel both engaged in vigorous discussions over the use of NSAIDs and oral glucocorticoids Another major change in recommendations for the treatment of systemic JIA is the use of bDMARDs as initial treatment or upon inadequate response to a short course of NSAIDs. The addition of csDMARDs is recommended only for persistent synovitis despite treatment with bDMARDs. This recommendation reflects growing understanding about the roles of specific cytokines in systemic JIA and the ability to induce remission with targeted therapy against IL-6 and IL-1 The use of IAGCs was extensively discussed. Recommendations from 2011 and 2019 to preferentially use triamcinolone hexacetonide for oligoarthritis There is much that remains to be learned. Studies must be performed to obtain high-quality data to fill in the evidentiary gaps",
            "(csDMARDs) Conventional synthetic DMARDs are strongly recommended if there is an inadequate response to scheduled NSAIDs and/or IAGCs for active oligoarthritis. Methotrexate is conditionally recommended as a preferred agent over leflunomide, sulfasalazine, or hydroxychloroquine (in that order). Despite an absence of comparator trials, methotrexate is the preferred agent, given the preponderance of evidence showing its long-term safety and efficacy in children With regard to the route of administration of methotrexate, the 2019 JIA guidelines conditionally recommended subcutaneous over oral administration for polyarthritis . This recommendation was conditional because the supporting evidence was of very low quality and patient preferences may guide choice of route of administration. There is little reason to suggest that methotrexate should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|</p>",
            "preferred bDMARD. Voting panelists deferred recommending a specific bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice Some voting panelists preferred starting with a short-acting agent such as anakinra, but in the absence of controlled studies, no preferred agent was endorsed. Patients/caregivers noted preference for fewer injections, if possible. As response to individual agents is variable, switching among and between IL-1 and IL-6 inhibitors when needed due to lack of efficacy or poor tolerability is appropriate. Concerns were expressed"
        ]
    }
]